Covered recipient · General Payments record
BRADLEY G SOMER
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$11,720.42
58 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $6,327.50 | 4 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,500.00 | 2 |
| Food and Beverage | $883.92 | 51 |
| Education | $9.00 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $4,461.50 | 3 |
| ARRAY BIOPHARMA INC | $2,920.00 | 1 |
| Gilead Sciences, Inc. | $1,617.82 | 4 |
| Bayer HealthCare Pharmaceuticals Inc. | $1,225.00 | 1 |
| Merck KGaA | $650.00 | 1 |
| Janssen Biotech, Inc. | $138.19 | 11 |
| Janssen Pharmaceuticals, Inc | $112.78 | 1 |
| PFIZER INC. | $98.44 | 7 |
| Amgen Inc. | $93.81 | 2 |
| Novartis Pharmaceuticals Corporation | $45.62 | 3 |
| AVEO Pharmaceuticals, Inc. | $37.33 | 2 |
| Astellas Pharma US Inc | $36.89 | 2 |
| Merck Sharp & Dohme LLC | $33.29 | 3 |
| Pharmacyclics LLC, an AbbVie Company | $31.33 | 2 |
| Myovant Sciences Inc. | $25.48 | 2 |
| EISAI INC. | $23.16 | 1 |
| Seagen Inc. | $22.18 | 1 |
| Exelixis Inc. | $19.53 | 1 |
| EMD Serono, Inc. | $16.76 | 1 |
| ADC Therapeutics America, Inc. | $16.21 | 1 |
| GENZYME CORPORATION | $14.39 | 1 |
| ABBVIE INC. | $14.33 | 1 |
| Genentech USA, Inc. | $13.83 | 2 |
| Coherus Biosciences Inc. | $13.65 | 1 |
| E.R. Squibb & Sons, L.L.C. | $13.27 | 1 |
| G1 Therapeutics, Inc. | $13.22 | 1 |
| Lilly USA, LLC | $12.41 | 1 |
Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRADLEY G SOMER
NPI 1851320691 · CMS profile ID 219649
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
GERMANTOWN, TN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1851320691?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRADLEY G SOMER, NPI 1851320691, CMS profile ID 219649. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851320691?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). BRADLEY G SOMER, NPI 1851320691, CMS profile ID 219649. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851320691?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- BRADLEY G SOMER, NPI 1851320691, CMS profile ID 219649, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1851320691?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
58 matching records · $11,720.42 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–58 of 58.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GENZYME CORPORATION | $14.39 | 02/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938912475 | CMS |
| Coherus Biosciences Inc. | $13.65 | 02/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956562449 | CMS |
| Novartis Pharmaceuticals Corporation | $12.41 | 02/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894394731 | CMS |
| Janssen Pharmaceuticals, Inc | $112.78 | 02/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886899219 | CMS |
| Janssen Biotech, Inc. | $16.23 | 01/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886555953 | CMS |
| Merck Sharp & Dohme LLC | $6.53 | 01/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944595892 | CMS |
| ADC Therapeutics America, Inc. | $16.21 | 01/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060941955 | CMS |
| AVEO Pharmaceuticals, Inc. | $18.55 | 01/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950102285 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $520,883.39 | 46 |
| PY2024 | Principal investigator | $750,330.42 | 75 |
| PY2023 | Principal investigator | $733,470.19 | 23 |
| PY2022 | Principal investigator | $538,638.95 | 43 |
| PY2021 | Principal investigator | $398,741.21 | 59 |
| PY2020 | Principal investigator | $260,292.96 | 59 |
| PY2019 | Principal investigator | $864,934.10 | 96 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
46 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,628.12 | 12/31/2025 | Non-covered Recipient Entity The West Clinic, PLLC dba West Cancer Center | A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician s Choice in 3L Advanced,Metastatic Gastroesophageal Adenocarcinoma Gastric Adenocarcinoma, Gastroesophageal Junction Adenoca | No dispute reported | 06/30/2026 | 1232924242 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $11,480.99 | 12/31/2025 | Non-covered Recipient Entity The West Clinic, P.C. | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma mRCC KEYNOTE | No dispute reported | 06/30/2026 | 1232926307 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $19,689.04 | 12/31/2025 | Non-covered Recipient Entity The West Clinic, PLLC dba West Cancer Center | A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Treatment with One Next generation Hor | No dispute reported | 06/30/2026 | 1232930053 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $11,014.20 | 12/31/2025 | Non-covered Recipient Entity The West Clinic, PLLC dba West Cancer Center | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph | No dispute reported | 06/30/2026 | 1232935407 |
| Principal investigator 1 | PFIZER INC. | $197.60 | 12/18/2025 | Non-covered Recipient Entity West Clinic Research Department | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228749677 |
| Principal investigator 1 | Genentech, Inc. | $10,750.00 | 12/16/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211671745 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 12/16/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211671748 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 12/16/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211671754 |
| Principal investigator 1 | Genentech, Inc. | $354.00 | 12/16/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211671759 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 12/16/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211671764 |
| Principal investigator 1 | Genentech, Inc. | $1,006.00 | 11/20/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211671722 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $20,818.55 | 11/19/2025 | Non-covered Recipient Entity The West Clinic, PLLC dba West Cancer Center | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph | No dispute reported | 06/30/2026 | 1232935405 |
| Principal investigator 1 | PFIZER INC. | $17,720.00 | 11/14/2025 | Non-covered Recipient Entity West Clinic Research Department | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228714847 |
| Principal investigator 1 | PFIZER INC. | $197.60 | 10/21/2025 | Non-covered Recipient Entity West Clinic Research Department | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228742991 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,668.00 | 10/17/2025 | Non-covered Recipient Entity The West Clinic, P.C. | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma mRCC KEYNOTE | No dispute reported | 06/30/2026 | 1232926305 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $99,585.60 | 08/31/2025 | Non-covered Recipient Entity The West Clinic, PLLC dba West Cancer Center | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph | No dispute reported | 06/30/2026 | 1232935409 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,117.00 | 07/23/2025 | Non-covered Recipient Entity WEST CANCER CENTER | Study of MEDI4736 Durvalumab With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer | No dispute reported | 06/30/2026 | 1185545669 |
| Principal investigator 1 | PFIZER INC. | $9,935.10 | 07/16/2025 | Non-covered Recipient Entity West Clinic Research Department | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228783399 |
| Principal investigator 1 | PFIZER INC. | $8,860.00 | 06/26/2025 | Non-covered Recipient Entity West Clinic Research Department | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228778285 |
| Principal investigator 1 | Amgen Inc. | $6,400.00 | 06/25/2025 | Non-covered Recipient Entity WEST CLINIC PC | A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression | No dispute reported | 06/30/2026 | 1246652081 |
| Principal investigator 1 | AstraZeneca UK Limited | $5,831.57 | 06/09/2025 | Non-covered Recipient Entity WEST CANCER CENTER AND RESEARCH INSTITUTE | ROSY-D Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment | No dispute reported | 06/30/2026 | 1185545667 |
| Principal investigator 1 | PFIZER INC. | $830.70 | 05/14/2025 | Non-covered Recipient Entity West Clinic Research Department | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228764697 |
| Principal investigator 1 | AstraZeneca UK Limited | $6,500.00 | 05/08/2025 | Non-covered Recipient Entity WEST CANCER CENTER | ROSY-D Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment | No dispute reported | 06/30/2026 | 1185545663 |
| Principal investigator 1 | PFIZER INC. | $8,860.00 | 05/01/2025 | Non-covered Recipient Entity West Clinic Research Department | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228772326 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $750.00 | 04/25/2025 | Non-covered Recipient Entity West Clinic Pharmacy | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 1176545937 |
| Principal investigator 1 | PFIZER INC. | $8,850.00 | 04/19/2025 | Non-covered Recipient Entity The West Clinic PLLC | A PHASE 2 RANDOMIZED OPENLABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600EMUTANT MSI HDMMR METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228794364 |
| Principal investigator 1 | PFIZER INC. | $418.60 | 04/16/2025 | Non-covered Recipient Entity West Clinic Research Department | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228779351 |
| Principal investigator 1 | PFIZER INC. | $96.00 | 04/07/2025 | Non-covered Recipient Entity TheWestClinicWestCancerCenter | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228759592 |
| Principal investigator 1 | PFIZER INC. | $90.00 | 04/07/2025 | Non-covered Recipient Entity TheWestClinicWestCancerCenter | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228761182 |
| Principal investigator 1 | PFIZER INC. | $160.00 | 04/07/2025 | Non-covered Recipient Entity TheWestClinicWestCancerCenter | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228769541 |
| Principal investigator 1 | PFIZER INC. | $1,249.30 | 03/28/2025 | Non-covered Recipient Entity West Clinic Research Department | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228787523 |
| Principal investigator 1 | Genentech, Inc. | $551.00 | 03/20/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211671590 |
| Principal investigator 1 | PFIZER INC. | $14,721.60 | 03/17/2025 | Non-covered Recipient Entity TheWestClinicWestCancerCenter | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228770118 |
| Principal investigator 1 | PFIZER INC. | $9,690.70 | 03/14/2025 | Non-covered Recipient Entity West Clinic Research Department | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228794244 |
| Principal investigator 1 | PFIZER INC. | $54.72 | 02/24/2025 | Non-covered Recipient Entity TheWestClinicWestCancerCenter | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228769290 |
| Principal investigator 1 | PFIZER INC. | $160.00 | 02/24/2025 | Non-covered Recipient Entity TheWestClinicWestCancerCenter | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228769596 |
| Principal investigator 1 | Amgen Inc. | $9,309.00 | 02/21/2025 | Non-covered Recipient Entity WEST CANCER CENTER | A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression | No dispute reported | 06/30/2026 | 1246652077 |
| Principal investigator 1 | PFIZER INC. | $1,249.30 | 02/14/2025 | Non-covered Recipient Entity West Clinic Research Department | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228769948 |
| Principal investigator 1 | PFIZER INC. | $7,360.80 | 02/10/2025 | Non-covered Recipient Entity TheWestClinicWestCancerCenter | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228769285 |
| Principal investigator 1 | Genentech, Inc. | $3,763.00 | 02/04/2025 | Non-covered Recipient Entity THE WEST CLINIC PC | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211671586 |
| Principal investigator 1 | PFIZER INC. | $54.72 | 01/27/2025 | Non-covered Recipient Entity TheWestClinicWestCancerCenter | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228761091 |
| Principal investigator 1 | PFIZER INC. | $418.60 | 01/25/2025 | Non-covered Recipient Entity West Clinic Research Department | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228720063 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $207,482.68 | 01/24/2025 | Non-covered Recipient Entity WEST CANCER CENTER | A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 | No dispute reported | 06/30/2026 | 1185545665 |
| Principal investigator 1 | PFIZER INC. | $80.00 | 01/15/2025 | Non-covered Recipient Entity TheWestClinicWestCancerCenter | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228769591 |
| Principal investigator 1 | PFIZER INC. | $1,249.30 | 01/15/2025 | Non-covered Recipient Entity West Clinic Research Department | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228798715 |
| Principal investigator 1 | PFIZER INC. | $180.00 | 01/14/2025 | Non-covered Recipient Entity TheWestClinicWestCancerCenter | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228720205 |